A biomarker panel doesn’t just confirm a protocol — it actively shapes which one gets recommended in the first place. Metabolic markers can shift which compounds make sense; inflammation markers can change dosing; hormone levels can rule certain protocols out entirely.
That’s why the panel comes before the recommendation, not after. A protocol proposed without baseline data isn’t personalized, it’s a guess — and guesses are exactly what physician review is there to catch.